Ipilimumab
An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
Year introduced: 2018(2012)
PubMed search builder options
Subheadings:
Tree Number(s): D12.776.124.486.485.114.224.060.798, D12.776.124.790.651.114.224.060.798, D12.776.377.715.548.114.224.200.798
MeSH Unique ID: D000074324
Entry Terms:
- Anti-CTLA-4 MAb Ipilimumab
- Anti CTLA 4 MAb Ipilimumab
- Ipilimumab, Anti-CTLA-4 MAb
- MDX 010
- MDX-010
- MDX010
- MDX-CTLA-4
- MDX CTLA 4
- Yervoy
See Also:
Pharmacologic Action: